* If you want to update the article please login/register
Patients with pT1-3, pN0-3, M0 breast tumors were randomised between adjuvant dose-dense doxorubicin-cyclophosphamide and docetaxel-cyclophosphamide in 2004 and 2012, according to an adjuvant dose-dense doxorubicin-cyclophosphamide and docetaxel-cyclophosphamide. Overall design: The MATADOR study has a total number of patients: 664. Tumor tissue from 604 patients was used for gene expression analysis. In 7 patients, the Library's preparations failed. For one patient's survival data, survival statistics were missing.
Source link: https://www.ncbi.nlm.nih.gov/bioproject/705699
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions